Christopher Benecchi - 16 Jan 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Operating Officer
Signature
Brandon Marsh, attorney in fact for Christopher Benecchi
Issuer symbol
SAGE
Transactions as of
16 Jan 2025
Transactions value $
$0
Form type
4
Filing time
21 Jan 2025, 16:11:21 UTC
Previous filing
14 Nov 2024
Next filing
14 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +20,000 +80.85% $0 44,737 16 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Options (Right to buy) Award $0 +40,000 $0 40,000 16 Jan 2025 Common Stock 40,000 $6.97 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of common stock issuable under 20,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on January 16, 2026.
F2 The securities awarded on January 16, 2025 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. Options to purchase 10,000 shares of common stock shall vest on the one year anniversary of January 16, 2025, with 30,000 shares vesting in 36 equal monthly installments thereafter.